Coronaviridae Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Coronaviridae Infections – Pipeline Review, H2 2016’, provides an overview of the Coronaviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Coronaviridae Infections

The report reviews pipeline therapeutics for Coronaviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Coronaviridae Infections therapeutics and enlists all their major and minor projects

The report assesses Coronaviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Coronaviridae Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Coronaviridae Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coronaviridae Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

CEL-SCI Corporation

GeneCure LLC

Gilead Sciences, Inc.

Hemispherx Biopharma, Inc.

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Kineta, Inc.

Nanotherapeutics, Inc.

NanoViricides, Inc.

Novavax, Inc.

Organic Vaccines

Phelix Therapeutics, LLC

Planet Biotechnology Inc.

Protein Sciences Corporation

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Coronaviridae Infections Overview 10

Therapeutics Development 11

Pipeline Products for Coronaviridae Infections - Overview 11

Pipeline Products for Coronaviridae Infections - Comparative Analysis 12

Coronaviridae Infections - Therapeutics under Development by Companies 13

Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes 15

Coronaviridae Infections - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Coronaviridae Infections - Products under Development by Companies 19

Coronaviridae Infections - Products under Investigation by Universities/Institutes 21

Coronaviridae Infections - Companies Involved in Therapeutics Development 22

AstraZeneca Plc 22

CEL-SCI Corporation 23

GeneCure LLC 24

Gilead Sciences, Inc. 25

Hemispherx Biopharma, Inc. 26

Humabs BioMed SA 27

Inovio Pharmaceuticals, Inc. 28

Kineta, Inc. 29

Nanotherapeutics, Inc. 30

NanoViricides, Inc. 31

Novavax, Inc. 32

Organic Vaccines 33

Phelix Therapeutics, LLC 34

Planet Biotechnology Inc. 35

Protein Sciences Corporation 36

Regeneron Pharmaceuticals Inc 37

Coronaviridae Infections - Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Combination Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

CEL-1000 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

D-3252 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

FBR-001 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

FDX-000 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

GS-5734 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

INO-4500 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

interferon alfa-n3 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

interferon beta-1a - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

KIN-1400 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

LCA-60 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Middle East respiratory syndrome coronavirus vaccine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Middle East respiratory syndrome coronavirus vaccine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Middle East respiratory syndrome coronavirus vaccine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Middle East respiratory syndrome vaccine - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Middle East respiratory syndrome vaccine - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

ML-188 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Monoclonal Antibody for Coronavirus Infection - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Monoclonal Antibody for SARS Virus Infections - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

RBD-219N1 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

REGN-3048 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

REGN-3051 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

SAB-301 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

SARS (virus like particle) vaccine - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

severe acute respiratory syndrome vaccine - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules for Viral Infections - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit 3CLpro for Coronavirus Infections - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

SSYA-10001 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Coronaviridae Infections - Dormant Projects 87

Coronaviridae Infections - Discontinued Products 90

Coronaviridae Infections - Product Development Milestones 91

Featured News & Press Releases 91

Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment 91

Aug 08, 2016: GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine 92

Jan 20, 2016: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection as a Treatment of Middle East Respiratory Syndrome 92

Nov 19, 2015: GeneOne Life Science and Inovio Pharmaceuticals’ MERS Vaccine Approved for First-in-Human Study 93

Oct 19, 2015: Inovio and Partner Advance MERS Vaccine 93

Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome 93

Jul 28, 2015: PNAS Paper Details Efficacy Of A Potent, Fully Human Antibody For The Treatment Of MERS 94

Jul 15, 2015: Hemispherx Biopharma Europe Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection for Treatment of Middle East Respiratory Syndrome 95

Jun 22, 2015: MERS coronavirus: Candidate vaccine gears up for clinical trials 95

Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections 96

Jun 16, 2014: Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS) 97

Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 98

Jun 06, 2013: Novavax Produces New Vaccine Candidate To Fight MERS-CoV Infection 99

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development for Coronaviridae Infections, H2 2016 11

Number of Products under Development for Coronaviridae Infections – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Coronaviridae Infections – Pipeline by AstraZeneca Plc, H2 2016 22

Coronaviridae Infections – Pipeline by CEL-SCI Corporation, H2 2016 23

Coronaviridae Infections – Pipeline by GeneCure LLC, H2 2016 24

Coronaviridae Infections – Pipeline by Gilead Sciences, Inc., H2 2016 25

Coronaviridae Infections – Pipeline by Hemispherx Biopharma, Inc., H2 2016 26

Coronaviridae Infections – Pipeline by Humabs BioMed SA, H2 2016 27

Coronaviridae Infections – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 28

Coronaviridae Infections – Pipeline by Kineta, Inc., H2 2016 29

Coronaviridae Infections – Pipeline by Nanotherapeutics, Inc., H2 2016 30

Coronaviridae Infections – Pipeline by NanoViricides, Inc., H2 2016 31

Coronaviridae Infections – Pipeline by Novavax, Inc., H2 2016 32

Coronaviridae Infections – Pipeline by Organic Vaccines, H2 2016 33

Coronaviridae Infections – Pipeline by Phelix Therapeutics, LLC, H2 2016 34

Coronaviridae Infections – Pipeline by Planet Biotechnology Inc., H2 2016 35

Coronaviridae Infections – Pipeline by Protein Sciences Corporation, H2 2016 36

Coronaviridae Infections – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 37

Assessment by Monotherapy Products, H2 2016 38

Assessment by Combination Products, H2 2016 39

Number of Products by Stage and Target, H2 2016 41

Number of Products by Stage and Mechanism of Action, H2 2016 43

Number of Products by Stage and Route of Administration, H2 2016 45

Number of Products by Stage and Molecule Type, H2 2016 47

Coronaviridae Infections – Dormant Projects, H2 2016 87

Coronaviridae Infections – Dormant Projects (Contd..1), H2 2016 88

Coronaviridae Infections – Dormant Projects (Contd..2), H2 2016 89

Coronaviridae Infections – Discontinued Products, H2 2016 90

List of Figures

List of Figures

Number of Products under Development for Coronaviridae Infections, H2 2016 11

Number of Products under Development for Coronaviridae Infections – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 38

Number of Products by Targets, H2 2016 40

Number of Products by Stage and Targets, H2 2016 40

Number of Products by Mechanism of Actions, H2 2016 42

Number of Products by Stage and Mechanism of Actions, H2 2016 42

Number of Products by Routes of Administration, H2 2016 44

Number of Products by Stage and Routes of Administration, H2 2016 44

Number of Products by Top 10 Molecule Types, H2 2016 46

Number of Products by Stage and Top 10 Molecule Types, H2 2016 46

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports